title: Immunogenicity of Human Interferon-Beta-Containing Pharmaceuticals.
abstract: Multiple sclerosis is a severe autoimmune disease with inflammatory component that continues to be resistant to treatment. One of the approaches retarding its progression is based on using nonspecific therapy with human interferon-beta (IFN-β)-containing pharmaceuticals. Neutralizing antibodies (NAbs) against genetically engineered pharmaceuticals developed by the patient's immune system, which reduce their therapeutic and biological activity, pose a serious problem. Cell lines sensitive to IFN-β activity also quantifying NAb level are applied because direct measurement of IFN-β antiviral activity is complicated. This study was aimed at standardization and validation of a reporter cell system for measuring anti-human IFN-β NAb titers, and evaluation data were obtained with samples from 33 patients with multiple sclerosis.
authors.affiliation: Center for Molecular Medicine, Pavlov First Saint Petersburg State Medical University, St. Petersburg, 197022, Russia. Nazarov19932@mail.ru.
authors.forename: V D
authors.initials: VD
authors.lastname: Nazarov
authors.forename: S V
authors.initials: SV
authors.lastname: Lapin
authors.forename: A V
authors.initials: AV
authors.lastname: Mazing
authors.forename: E P
authors.initials: EP
authors.lastname: Evdoshenko
authors.forename: A A
authors.initials: AA
authors.lastname: Totolian
mesh_terms: D057134:Antibodies, Neutralizing / Q000097:blood / Q000276:immunology*; D045744:Cell Line, Tumor; D004351:Drug Resistance / Q000187:drug effects* / Q000276:immunology; D005260:Female; D006801:Humans; D016899:Interferon-beta / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D008297:Male; D009103:Multiple Sclerosis / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*
chemical_list: D057134:Antibodies, Neutralizing; D016899:Interferon-beta